Is axitinib/axitinib a targeted therapy drug for advanced renal cancer?

Axitinib/Axitinib is a targeted therapy drug mainly used for the treatment of advanced renal cell carcinoma (RCC). As a tyrosine kinase inhibitor (TKI), axitinib inhibits the proliferation and growth of cancer cells by intervening in specific tyrosine kinase signaling pathways. Its main mechanism of action is to prevent the interaction between tumor cells and their growth signals while inhibiting the formation of new blood vessels, a process called anti-angiogenesis.

Axitinib is suitable for patients with advanced kidney cancer who have failed or relapsed after other treatments. In clinical practice, the drug can be used as a first-line treatment option, especially in certain cases, and may be combined with immunotherapy drugs to enhance efficacy. In addition, axitinib is being evaluated in clinical trials in other cancer types, indicating that its potential applications are expanding.

The drug targets a variety of tyrosine kinases, especially vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and other tumor-related receptors, inhibiting the activity of these receptors, thereby reducing the blood supply and nutrient supply of the tumor, thereby inhibiting tumor growth and metastasis. The anti-angiogenic mechanism of axitinib makes it play an important role in the tumor microenvironment, especially at the stage when tumors rely on new blood vessels to obtain nutrients and oxygen.

Clinical studies have shown that the therapeutic effect of axitinib is significant, and common adverse reactions include hypertension, fatigue, and oral ulcers. These reactions are similar to most tyrosine kinase inhibitors. Therefore, during treatment with axitinib, patients need to regularly monitor blood pressure and other related indicators in order to promptly deal with possible adverse reactions.

Reference materials:https://www.cancerresearchuk.org/about-cancer/treatment/drugs/axitinib